东亚药业(605177) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 330,315,024.50, representing a year-over-year increase of 3.49%[5] - The net profit attributable to shareholders for Q3 2023 was CNY 30,951,414.14, reflecting a significant increase of 62.11% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2023 was CNY 27,459,006.29, up 66.05% year-over-year[5] - The basic earnings per share for Q3 2023 was CNY 0.27, an increase of 58.82% compared to the previous year[6] - The diluted earnings per share for Q3 2023 was CNY 0.23, representing a year-over-year increase of 35.29%[6] - The net profit attributable to shareholders for the year-to-date period was CNY 85,562,429.83, up 40.11% year-over-year[5] - Net profit for the third quarter of 2023 was ¥85,562,429.83, compared to ¥61,068,549.96 in the same quarter of 2022, representing an increase of 40.2%[22] - The net profit attributable to the parent company for Q3 2023 was ¥85,562,429.83, an increase from ¥61,068,549.96 in Q3 2022, representing a growth of approximately 40%[23] Assets and Liabilities - Total assets at the end of Q3 2023 reached CNY 3,382,713,418.70, marking a 36.88% increase from the end of the previous year[6] - The total assets as of the end of the third quarter of 2023 amounted to ¥3,382,713,418.70, up from ¥2,471,356,543.29 at the end of the previous year, indicating a growth of 36.8%[19] - Total liabilities increased to ¥1,331,433,215.64 in the third quarter of 2023, compared to ¥631,567,287.30 in the same period of 2022, marking a rise of 111.1%[19] - Long-term borrowings increased to ¥87,500,000.00 in the third quarter of 2023, compared to ¥15,000,000.00 in the same period of 2022, showing a growth of 483.3%[19] - The total equity attributable to shareholders reached ¥2,051,280,203.06, up from ¥1,839,789,255.99 in the previous year, representing an increase of 11.5%[19] Cash Flow - The company reported a cash flow from operating activities of -CNY 97,862,993.47 for the year-to-date period[6] - The net cash flow from operating activities for the first three quarters of 2023 was -¥97,862,993.47, an improvement compared to -¥134,513,081.58 in the same period of 2022[25] - Total cash inflow from financing activities in Q3 2023 was ¥855,990,566.04, significantly higher than ¥67,000,000.00 in Q3 2022[26] - The net increase in cash and cash equivalents for Q3 2023 was ¥465,040,517.28, compared to a decrease of -¥157,276,738.63 in Q3 2022[26] - The company’s cash and cash equivalents at the end of Q3 2023 stood at ¥966,622,139.54, compared to ¥389,934,636.35 at the end of Q3 2022[26] Inventory and Receivables - The inventory increased to ¥592,372,964.49, compared to ¥482,836,761.74 at the end of 2022, indicating a 22.7% rise[17] - The company reported accounts receivable of ¥98,453,246.26, down from ¥182,316,396.08 at the end of 2022, indicating a reduction of 46.0%[17] Research and Development - Research and development expenses for the third quarter of 2023 were ¥53,599,947.01, significantly higher than ¥30,313,844.36 in the same quarter of 2022, reflecting an increase of 76.6%[22] Future Plans - The company plans to expand its market presence through the development of new products and technologies, focusing on innovative drug formulations[15] - The company plans to continue expanding its market presence and investing in new product development to sustain growth momentum in the upcoming quarters[22] Shareholder Information - The company’s actual controllers are Chi Zhengming and Chi Cheng, holding 41.48% and 6.85% of shares respectively, with a combined voting power of 9.06%[14] - The company’s stockholders include significant institutional investors, with the top ten shareholders holding a substantial portion of the company’s equity[14] Financial Stability - The company’s total liabilities and equity structure will be closely monitored following the recent bond issuance to ensure financial stability[15]